Multiple Myeloma Molecular Monitoring Study

NCT03421132

NULLOBSERVATIONAL

Horizon Health Network

96 participants

Started 2018-02-20 · Completed 2026-03-31

Status: Active Not Recruiting (as of 12-23-2025)

Conditions

Multiple Myeloma

Interventions

Linked Papers (from SciSciNet-V2)

Total Papers26

Background

12

Result

0

Derived

0

Unknown

14

View on ClinicalTrials.gov

Total Citations Per Year

Brief Summary

The investigators will track 250 multiple myeloma patients across Canada over time, using new lab tests to evaluate their blood and bone marrow, as they receive standard of care treatment. The main hypothesis is that these tests will allow clinicians to better diagnose and manage multiple myeloma, improving patients' quality of life overall.

Sort by:

Background Papers23

Initial genome sequencing and analysis of multiple myeloma

1,394 citations

Initial genome sequencing and analysis of multiple myeloma

1,394 citations

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance

Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study

Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

Prospective Evaluation of Magnetic Resonance Imaging and [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study

Prospective Evaluation of Magnetic Resonance Imaging and [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma

Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma

Minimal residual disease in multiple myeloma: bringing the bench to the bedside

Minimal residual disease in multiple myeloma: bringing the bench to the bedside

Result Papers0

No result papers linked

Derived Papers0

No derived papers linked

Unknown Papers14

Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer

4,315 citations

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

4,027 citations

Cell-free nucleic acids as biomarkers in cancer patients

2,630 citations

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

2,268 citations

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

IMWG consensus on risk stratification in multiple myeloma

Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma

PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma

Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival.

The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer

Loss of Heterozygosity at Tumor Suppressor Genes Detectable on Fractionated Circulating Cell-Free Tumor DNA as Indicator of Breast Cancer Progression

Deep Sequencing Reveals Myeloma Cells in Peripheral Blood in Majority of Multiple Myeloma Patients